BRUKINSA (zanubrutinib)

About beigene

BeiGene has rapidly evolved from a research-focused startup into a leading global oncology company with a vertically integrated model spanning R&D, manufacturing, and commercialization. Its strategic pivot to internal R&D yielded the blockbuster-in-waiting BRUKINSA, which has achieved multiple FDA approvals and is competing head-to-head with established BTK inhibitors. The company's strategy leverages its deep roots in China for development efficiency and cost-effective manufacturing, while its substantial infrastructure in the U.S. and Europe supports global commercial ambitions.

About beigene

BeiGene has rapidly evolved from a research-focused startup into a leading global oncology company with a vertically integrated model spanning R&D, manufacturing, and commercialization. Its strategic pivot to internal R&D yielded the blockbuster-in-waiting BRUKINSA, which has achieved multiple FDA approvals and is competing head-to-head with established BTK inhibitors. The company's strategy leverages its deep roots in China for development efficiency and cost-effective manufacturing, while its substantial infrastructure in the U.S. and Europe supports global commercial ambitions.

About beigene

BeiGene has rapidly evolved from a research-focused startup into a leading global oncology company with a vertically integrated model spanning R&D, manufacturing, and commercialization. Its strategic pivot to internal R&D yielded the blockbuster-in-waiting BRUKINSA, which has achieved multiple FDA approvals and is competing head-to-head with established BTK inhibitors. The company's strategy leverages its deep roots in China for development efficiency and cost-effective manufacturing, while its substantial infrastructure in the U.S. and Europe supports global commercial ambitions.

About beigene

BeiGene has rapidly evolved from a research-focused startup into a leading global oncology company with a vertically integrated model spanning R&D, manufacturing, and commercialization. Its strategic pivot to internal R&D yielded the blockbuster-in-waiting BRUKINSA, which has achieved multiple FDA approvals and is competing head-to-head with established BTK inhibitors. The company's strategy leverages its deep roots in China for development efficiency and cost-effective manufacturing, while its substantial infrastructure in the U.S. and Europe supports global commercial ambitions.

About beigene

BeiGene has rapidly evolved from a research-focused startup into a leading global oncology company with a vertically integrated model spanning R&D, manufacturing, and commercialization. Its strategic pivot to internal R&D yielded the blockbuster-in-waiting BRUKINSA, which has achieved multiple FDA approvals and is competing head-to-head with established BTK inhibitors. The company's strategy leverages its deep roots in China for development efficiency and cost-effective manufacturing, while its substantial infrastructure in the U.S. and Europe supports global commercial ambitions.

About beigene

BeiGene has rapidly evolved from a research-focused startup into a leading global oncology company with a vertically integrated model spanning R&D, manufacturing, and commercialization. Its strategic pivot to internal R&D yielded the blockbuster-in-waiting BRUKINSA, which has achieved multiple FDA approvals and is competing head-to-head with established BTK inhibitors. The company's strategy leverages its deep roots in China for development efficiency and cost-effective manufacturing, while its substantial infrastructure in the U.S. and Europe supports global commercial ambitions.

About BeOne Medicines

BeOne Medicines is a global, publicly traded oncology company with a mission to deliver transformative cancer treatments through scientific excellence and rapid execution. The company has established itself with two commercial-stage assets, BRUKINSA and TEVIMBRA, and a deep, multi-modality pipeline targeting high-burden blood cancers, solid tumors, and rare malignancies. Its strategy leverages a global clinical and commercial footprint, significant R&D investment, and a multi-platform technology approach to capture substantial market opportunities in oncology.

About BeOne Medicines

BeOne Medicines is a global, publicly traded oncology company with a mission to deliver transformative cancer treatments through scientific excellence and rapid execution. The company has established itself with two commercial-stage assets, BRUKINSA and TEVIMBRA, and a deep, multi-modality pipeline targeting high-burden blood cancers, solid tumors, and rare malignancies. Its strategy leverages a global clinical and commercial footprint, significant R&D investment, and a multi-platform technology approach to capture substantial market opportunities in oncology.

Therapeutic Areas